Oura IPO: Strong Growth, but a $2.1bn Offering Stalls

Oura IPO: Strong Growth, but a $2.1bn Offering Stalls

SERRARI GROUP / ANALYST DESK — US WEARABLE HEALTH / DELAYED IPO

A profitable hardware-plus-membership model did not overcome a tougher valuation window or the offer's heavy secondary component.

$1.215bn — Nine-month revenue to June 2026

74% — Nine-month revenue growth year-on-year

$42 — Midpoint of postponed $40–$44 range

SERRARI IPO RESEARCH SERIES | RESEARCH CUT-OFF: 09 NOVEMBER 2026

RESEARCH & MARKET EDUCATION • NOT A SECURITIES OFFER OR PERSONAL ADVICE

Executive take: demand was strong; pricing was not

A delayed offer is not proof of business weakness or an imminent relaunch.

What happened

Oura postponed its planned Nasdaq IPO on 29 September 2026 despite receiving investor interest. No new trading date was announced.

Why it matters

The planned 50m-share offering at $40–$44 would have raised $2.0bn–$2.2bn before fees, with a large secondary component.

Operating case

Nine-month revenue grew 74%, membership revenue rose 121% and the company generated $328m in operating cash flow.

Serrari assessment

A successful relaunch requires not just demand but agreement on valuation and the balance between new capital and insider liquidity.

IPO mechanics: price, float and postponement

The prospectus was preliminary; the transaction did not price or complete.

03 Sep: public filing

Oura publicly filed its S-1 describing a health ring business with hardware and recurring memberships.

21 Sep: amended terms

The S-1/A described 50m shares at an indicative $40–$44 range and a proposed OURA ticker.

29 Sep: postponed

Management cited IPO market uncertainty. The filing was not declared effective as a completed share sale.

09 Nov: still not closed

The original terms are historical proposal terms, not a currently executable IPO price or guaranteed late-2026 listing.

Business quality: device economics and retention

The subscription model is attached to device adoption, not independent of it.

Hardware: ~80% of sales

Ring purchases are the primary revenue engine and carry inventory, returns, production and distribution exposure.

Membership: ~20% of sales

Paid features create a recurring layer; 94%+ of activations have historically converted to paid members, per prospectus.

Conversion flywheel

Every new ring creates a membership opportunity, but sustained revenue relies on retention and a compelling upgrade cycle.

Economics to monitor

Cohort retention, paid member churn, device replacement frequency, returns, supplier concentration and retail-channel economics.

Revenue mix: the subscription layer is growing

The figures are periods from the S-1; nine-month figures are not full fiscal years.

Metric comparison (periods labeled)

FY2024 hardware: 331.20m USD · FY2024 membership: 75.50m USD · FY2025 hardware: 749.40m USD · FY2025 membership: 158.50m USD · 9M2026 hardware: 974.00m USD · 9M2026 membership: 240.50m USD

Period note

FY2024 and FY2025 are 12-month periods. Nine months to June 2026 is not directly comparable to full years.

Mix change

Membership rose to about 19.8% of nine-month sales, from 17.5% in FY2025.

Profit, cash and reinvestment

Operating profit and cash generation support a different profile from cash-burning growth IPOs.

Gross margin

Nine-month gross margin reached 54.5% versus 51.0% in the comparable 2025 period.

Operating income

Nine-month operating income was $71.2m, rising from $60.3m despite increased R&D and marketing expenditure.

Operating cash flow

The filing shows $328.0m of operating cash flow and $66.2m of capex for nine months to June 2026.

Equity accounting caution

Net income of $60.8m is different from net loss attributable to common shareholders after preferred-stock deemed dividends.

Capital structure: primary versus secondary

The offering size overstated the new money earmarked for Oura itself.

13.5m primary shares

The prospectus indicated 13.5m new shares. At $42, their illustrative gross sale value would be $567m.

36.5m secondary shares

The rest of the initial 50m-share base would be sold by existing holders, implying $1.533bn gross at midpoint.

Proposed $13.48bn equity value

Approximately 320.95m diluted shares multiplied by $42 gives the indicative post-offering equity capitalization.

Use of proceeds

Company proceeds and employee-equity tax settlement needs differ from liquidity provided to shareholders; read the cash allocation carefully.

Price sensitivity: no definitive clearing level

The difference between indicative offer value and investor willingness to pay can block an otherwise viable listing.

Illustrative sensitivity / market values

$34/share: 10.91bn USD · $42/share: 13.48bn USD · $50/share: 16.05bn USD

Valuation basis

Illustrative equity values assume about 320.95m post-offering shares, without changing dilution.

Trailing sales check

Midpoint $13.48bn / estimated $1.425bn trailing revenue = ~9.46x P/S.

How the IPO market forced the decision

Higher rates and volatile risk appetite change the threshold for premium consumer-tech multiples.

Discount-rate channel

A higher required equity return reduces the present value of future subscription earnings and warrants lower multiples.

Hardware classification

Investors may value Oura as a device manufacturer with subscriptions rather than as a pure software platform.

Secondary mix

Large insider sales can amplify perceptions of liquidity-seeking even if business financials remain strong.

Flexibility advantage

Positive operating cash generation provides management some ability to wait for more favorable conditions.

Competitive advantage versus execution risk

Device design and data usefulness matter, but recurring economics should be underwritten conservatively.

Moat: health data

Longitudinal biometric insights may support differentiation, engagement and subscription retention.

Moat: form factor

Comfort, continuous wear and retail distribution support accessibility relative to larger wearable devices.

Risk: upgrade cycles

Device replacement is discretionary and can weaken when consumers cut spending.

Risk: data and claims

Privacy, consent, health interpretation and regulatory boundaries create continuing compliance costs.

Risk map: healthy cash flows do not remove market risk

Figure: Risk map — healthy cash flows do not remove market risk.

Scenario map: relaunch or remain private

No timeline is guaranteed by the September filing.

Disciplined relaunch

The company returns with a lower range or smaller secondary component and clears a more selective book.

Wait for stronger results

Management delays further to demonstrate subscription expansion and earnings durability before price discovery.

Valuation reset

A lower multiple reduces insider proceeds and reprices the premium implied by the initial 50m-share offer.

Market window deteriorates

Rising yields and retail-stock volatility extend the delay, even if operating revenue keeps growing.

Monitoring dashboard: six variables before relaunch

An amended range and shareholder mix matter more than placeholders.

Updated S-1 — Changes in offering size, shares and proceeds.

Hardware sell-through — Units sold and retail channel performance.

Membership cohorts — Net additions, renewal and monetization.

Cash quality — Cash flow versus working-capital effects.

Price discovery — Roadshow demand at a revised multiple.

Re-approval — Effective registration and final pricing.

Market assessment: what the evidence supports

Financial and listing facts are separated from analyst scenarios.

Serrari assessment: a viable business met a narrow IPO window

Oura has operating cash flow and fast-growing membership revenue, but the proposed IPO also offered substantial liquidity to shareholders. The first relaunch question is whether public investors will accept a premium valuation for a company still predominantly dependent on hardware.

$13.48bn — Indicative capitalization at the $42 midpoint

~9.46x — Midpoint capitalization / estimated TTM sales

$261.8m — Nine-month operating cash less capex, simple FCF

THE NEXT DECISION POINT

Watch for an amended prospectus, a revised secondary mix and an effective filing; the original September price range is not live.

Sources, methodology and limitations

SERRARI GROUP / ANALYST DESK

Use the linked descriptive phrases below to open the supporting filing, announcement or market record.

R1 — September amended S-1 and audited historic results

R2 — First public S-1 registration statement

R3 — Postponement announcement and market context

R4 — Deal structure, secondary component and investor demand

R5 — Reported health-tech IPO postponement details

METHODOLOGY & COMPARABILITY

TTM revenue = FY2025 revenue + 9M2026 revenue − 9M2025 revenue = ~$1.425bn. Equity sensitivities use 320.945m prospectus-indicated post-offering shares. FCF proxy = 9M operating cash flow less purchases of property, equipment and intangibles, without other adjustments.

ANALYST INTERPRETATION & CAUTIONS

All opinions and risk ranks are qualitative analyst judgments rather than probability estimates or financial advice. Figures are as of the stated source dates, not a real-time quote service. Offering terms can change. No recommendation to buy, sell or subscribe to any security is made.

Prepared 09 November 2026 | Serrari Group | Research and market education